Investors Urged to Act Before September 24, 2024
LOS ANGELES, Sept. 11, 2024 – The Schall Law Firm emphasizes a significant chance for investors in MacroGenics, Inc. (“MacroGenics” or “the Company”) with the ticker MGNX. Shareholders who acquired company securities between March 7, 2024, and May 9, 2024, inclusive (the “Class Period”), are advised to engage with the firm before September 24, 2024.
Allegations of Misleading Statements
During the Class Period, the Company purportedly disseminated false and deceptive information to the public. MacroGenics purportedly promoted optimistic interim safety data results from the TAMARACK Phase 2 study. However, on May 9, the Company unveiled updated safety and efficacy information for its cancer treatment study, TAMARACK. Subsequently, it was revealed that the Company’s public declarations were misleading throughout the class period, resulting in investors experiencing financial losses.
Legal Recourse for Affected Shareholders
Shareholders who suffered losses have the option to participate in the class action lawsuit to seek recovery. The Schall Law Firm, renowned for its expertise in securities class action lawsuits and shareholder rights litigation, stands ready to represent affected investors worldwide.
Engage with The Schall Law Firm
If you are a shareholder affected by the alleged violations, it is advisable to contact Brian Schall of The Schall Law Firm based in Los Angeles, California. The firm’s dedicated legal team can provide information regarding your rights at no cost. For further details, interested parties can visit www.schallfirm.com or reach out via email at bschall@schallfirm.com.
View the original content to download multimedia:Original Source
SOURCE The Schall Law Firm